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Abstract
Background—Alcoholic hepatitis (AH) is the most florid manifestation of alcoholic liver 
disease which accounts for significant morbidity, mortality and financial burden. Aim of this study 
is to evaluate temporal trend of hospitalizations from alcoholic hepatitis and evaluate its financial 
impact.
Methods—The National Inpatient Sample (NIS) databases (from 2002 to 2010) which are 
collected as part of Healthcare Cost and Utilization Project by Agency for Healthcare Research 
and Quality were utilized. Individuals with age ≥ 21 years were included. The hospitalizations 
with primary diagnosis of AH were captured by ICD-9 codes. The national estimates of 
hospitalization were derived using sample weights provided by NIS. Simple linear regression 
method was used to assess trends in mortality and length of stay over time.
Results—We observed the increased in total cases of AH-related hospitalization from 249,884 
(0.66% of total admission in 2002) to 326,403 (0.83% of total admission in 2010). The significant 
increase in the total admission rate was attributable mainly to the rise in inpatient hospitalization 
for secondary diagnosis of AH (0.48% in 2002 to 0.67% in 2010). Most of the AH related 
hospitalization were males. Hepatic encephalopathy was found to be the most common admitting 
diagnosis for individuals hospitalized with secondary diagnosis of AH (8.9% in 2002 and 8.6% in 
2010). There was a significant decrease in inpatient mortality for primary diagnosis of AH from 
10.07 % (in 2002) to 5.76% (in 2010) (absolute risk reduction: 4.3%). Average cost of 
hospitalization related to primary diagnosis of AH was $27,124 and $46,264 in 2002 and 2010, 
respectively. After adjusting for inflation, the additional cost of each hospitalization seemed to 
increase by 40.7% in 2010 compared to 2002 (additional cost per hospitalization $11,044 in 2010 
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compared to 2002). Federal (Medicare) or state (Medicaid) supported health insurance program 
are the main primary expected payers for these AH hospitalizations (~25% – 29%). Despite 
increase in cost per hospitalization, length of stay for hospitalization due to primary diagnosis of 
AH was not observed to decrease substantially over time (6.7 days in 2002 to 6.1 days in 2010).
Conclusion—AH-related hospitalization continued to increase during the study period, despite 
the decreasing in the in-hospital mortality rate. Substantial increases in healthcare cost and 
utilization among hospitalized AH patients were observed.
Keywords
alcoholic hepatitis; financial burden; National Inpatient Sample database
BACKGROUND
Alcoholic liver disease includes a spectrum of liver disease ranging from reversible fatty 
liver to alcoholic hepatitis (AH), and cirrhosis 1. AH presents as an acute hepatic injury in 
patients who consume excessive amounts of alcohol 2. In mild cases, patients have a 
favorable outcome with alcohol abstinence. However, those with severe disease have a high 
30-day mortality rate 1.
There are no strong epidemiological data on the incidence of AH in the US. In Denmark, the 
annual incidence rate of alcoholic hepatitis rose from 37 to 46 per 100,000 for men and from 
24 to 34 per 100,000 for women, during the study period from 1999–2008 3. Further, the 
overall 5-year mortality was 56% (47% in those without cirrhosis, and 69% in cases with 
cirrhosis) 3.
While the healthcare and economic burden for other liver diseases such as hepatitis B or C 
are expected to decrease in the next decade 4, the problem of liver disease attributable to the 
use of alcohol will remain significant 5. Recent studies demonstrated the increasing levels of 
alcohol consumption in the United States 6, 7. More importantly, drinking is starting at an 
earlier age 8–10 with binging becoming more common pattern 11. Taken together, these 
trends in alcohol consumption will likely cause substantial health, social, and economic 
burdens related to alcoholic liver disease, with increasing numbers of patients requiring 
hospitalization and the need for the outpatient care to provide support for these patients 5.
We previously examined the clinical characteristics and risk factors associated with 
mortality in hospitalized alcoholic hepatitis patients in the United States using the 2007 
National Inpatient Sample 12. In that study, we found that hospitalized AH patients resulted 
in significant healthcare cost and utilization 12. The average total charges during 
hospitalization for AH were higher than that from acute myocardial infarction, acute 
cerebrovascular disease, and acute pancreatitis 13.
Because of the current limitations and therapeutic options for patients with AH, the overall 
mortality especially in those with severe AH remains high 1. However, the data regarding 
inpatient mortality, healthcare utilization for patients with AH over the past decade are 
lacking. We hypothesized that i) the rate of inpatient admission secondary to AH increased 
over time and ii) the in-hospital mortality secondary to AH should not change due to the 
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limitation in the effectiveness of the currently available therapies. We analyzed the NIS data 
from 2002–2010 to determine the trends in rate of inpatient admission, outcome, 
hospitalization costs, financial burden, and mortality for hospitalized AH patients in the 
United States.
METHODS
Data source
The NIS database is part of the Healthcare Cost and Utilization Project (HCUP), sponsored 
by the Agency for Healthcare Research and Quality (AHRQ)14. The Nationwide Inpatient 
Sample (NIS) is the largest all-payer inpatient care database in the United States, containing 
data on more than seven million hospital stays annually from approximately 1,000 hospitals, 
constituting a 20% stratified sample of all U.S. hospitals. All data were weighted using 
discharge level values, based on the relative proportion of the total U.S. hospital patient 
population accounted for by that record, to produce 100% national estimates.
Subjects who were 21 years old or older who were hospitalized with the diagnosis of AH 
from 2002–2010 were included. AH was based on the following International Classification 
of Diseases-Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis codes 
(571.1). If this code was listed in the first position in the database, the admission was 
considered to be a primary AH hospitalization; otherwise, the admission was considered to 
be a secondary AH.
One of the outcomes in our study was the inpatient mortality in subjects with AH. The 
following ICD-9 codes were also used to identify known risk factors related to mortality in 
these patients: acute renal failure (584.50–70, 584.80–90, 586.00, and 593.90), GI bleeding 
(578.0–9), and sepsis (38.00–38.90).
Patient age, race (white, black, Hispanic, others), gender, household income, geographic 
region of treatment (Northeast, South, Midwest, and West) were abstracted. The types of 
hospitals were categorized into teaching/community and urban/rural location. The primary 
payer for the hospitalization was categorized as Medicare, Medicaid, private insurance, self-
pay, or other. Outcome-related measures were presented separately for both primary and 
secondary diagnoses of AH which included in-hospital mortality, length of stay, and 
discharge disposition. Discharge disposition was categorized as routine, short term hospital, 
skilled nursing facility, and home health care.
Statistical analysis
All statistical analyses were performed using the sampling weights and stratified sample 
design of the NIS to obtain nationally representative estimates. Descriptive statistics were 
presented as mean ± SD for continuous variables and frequencies for categorical variables. 
Annual rates of primary and secondary AH hospitalizations were calculated by dividing the 
number of hospitalizations with AH by the total inpatient admissions in the US in a given 
year. Changes in hospitalization rates and healthcare costs between 2002 and 2010 were 
determined with simple regression analysis. Statistical analyses were performed using SAS 
9.3 (Cary, NC).
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RESULTS
National estimates of AH-related hospitalization rates in the US from 2002–2010
We observed the increased in total cases of AH-related hospitalization from 249,884 (0.66% 
of total admission in 2002) to 326,403 (0.83% of total admission in 2010). The significant 
increase in the total admission rate was attributable mainly to the rise in inpatient 
hospitalization for secondary diagnosis of AH (0.48% in 2002 to 0.67% in 2010, Table 1). 
Hepatic encephalopathy was found to be the most common admitting diagnosis for 
individuals hospitalized with secondary diagnosis of AH (8.9% in 2002 and 8.6% in 2010). 
We observed no changes in the rate of admission for primary diagnosis of AH during this 
period (~0.16–0.18%).
Demographics and clinical characteristics of hospitalized AH patients in the US
The mean age of patients hospitalized with a diagnosis of AH over this period was 53 years 
old. The majority of hospitalized patients were men (73%) and white (65%–70%). The 
majority of cases had the household income in the first (~32%) quartile (Table 2).
Sources of admission and types of facilities for hospitalized AH patients
Hospitalized AH patients were admitted through local emergency department (64%–74%). 
There were no significant changes in the source of admission over this period except that the 
admission through emergency room was significantly decreased in 2010. Majority of cases 
were hospitalized into the hospitals which were located in the urban area (86%–90%) (Table 
3).
Fifty to sixty percent of cases were admitted into ‘non-teaching’ hospitals. There were 
significant geographic variations in hospitalized cases. We found that 33%–38% of 
hospitalized cases were in the Southern states; which was significantly higher than that 
admitted to other regions (p < 0.05) (Table 3).
Healthcare costs and outcomes related to hospitalizations from AH in the US
During the study period, there were no changes in the average length of stay for overall AH 
admissions (6.6 days in 2002 and 5.9 days in 2010). There were no differences in the length 
of hospital stay among patients with either primary or secondary diagnosis of AH (Table 4).
Majority of patients (62%–65%) were discharged to home with outpatient follow up visit. 
About 13%–14% of these cases were transferred to skilled nursing facility upon discharge. 
Though most patients had medicare; there were no differences in the payer sources among 
medicare carriers and those with medicade or private insurers (p< 0.05, Table 4).
The overall in-hospital mortality of AH cases was significantly decreased from 8% in 2002 
to 5.1% in 2010 (p < 0.05). In the detailed analysis, in-hospital mortality rates significantly 
decreased for both primary (10.1% in 2002 to 5.8% in 2010, p < 0.05) and secondary AH 
(7.2% in 2002 to 4.9% in 2010, p < 0.05) hospitalizations (Table 4). Among patients who 
died during the hospitalization, the rate of renal failure was noted to decrease significantly 
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from 43.6% in 2002 to 34.3% in 2010. However, the rate of sepsis among these cases 
increased from 26.7% in 2002 to 37.8% in 2010 (Table 5, Figure 2).
Despite no substantial changes in the length of stay, the overall hospitalization cost was 
increased substantially from $25,276 in 2002 to $40,870 in 2010. The total hospital charges 
for patients with primary diagnosis of AH ($27,124 – $46,264) were significantly higher 
than those with secondary diagnosis ($24,594 – $39,539) of AH during the study period (p < 
0.05, Table 4).
DISCUSSION
AH continues to be a cause of considerable mortality and morbidity especially in heavy 
drinkers 1. Our study demonstrated an increasing trend in AH-related hospitalizations in the 
US from 2002–2010, primarily due to secondary diagnosis of AH. We observed that the 
inpatient mortality rate was significantly decreased during this period. However, financial 
charges among hospitalized AH subjects remained high and increased substantially, despite 
little changes in the total length of stay.
The increase in hospitalization rate of AH over the past decade attests the notion that AH 
continues to be a major health problem in the US. This observation coincides with the report 
on the increasing levels of alcohol consumption 7 and also binge drinking 11 in the US. 
Though recent data showed the shift in alcohol drinking starting at the younger age, we 
found no difference in the mean age of hospitalized AH patients during the study period. In 
general, women are more susceptible than men to the adverse effects of alcohol and they 
develop AH after a shorter period and smaller amounts of alcohol use than men. However, 
in our study, we observed significantly higher proportion of male in hospitalized AH 
patients. This finding is not surprising as it has been shown that more men drink alcohol 
above the ‘safety range’ than women 15.
In agreement with our previous report, hospitalized AH patients result in significant 
healthcare cost and utilization 12. Patients with AH were hospitalized in different geographic 
locations especially in the urban areas. We found that federal (Medicare) or state (Medicaid) 
supported health insurance program are the main primary expected payers. Our findings 
were compatible with the levels of socioeconomic status which was measured by household 
income national quartile of the study cohort; in which majority of patients had the annual 
household income in the first quartile range.
During the study period, we found that financial charges among hospitalized AH subjects 
remained high, despite little changes in the total length of stay. It is likely that the rising in 
hospital charges is secondary to the rising in healthcare cost in the United States over the 
past decade 16.
It is surprising to observe the decrease in overall mortality among hospitalized AH patients 
over the past decade, despite the limitation or the new advancement in the treatment of 
AH 1. Using the NIS dataset, we have previously shown that the significant increase in 
mortality of AH patients who developed infections (i.e. sepsis or SBP) and acute renal 
failure during the hospital stay 12. Our observations regarding the decreasing in mortality 
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might be contributed to the early treatment of infections or fluid management to prevent the 
onset of acute renal failure. To support this hypothesis, we analyzed several known factors 
which are associated with mortality among patients with AH. Interestingly, we observed the 
decreasing trends of acute renal failure among cases who died during the hospital stay from 
2002–2010. However, our results need to be cautiously interpreted. First, we do not have 
access to the etiology of death of these patients in the NIS database. The presence of acute 
renal failure and/or sepsis during the hospital stay might, in fact, not relate to the actual 
cause of death since we do not have the information whether renal failure/sepsis has 
resolved during the hospitalization. Second, NIS data only captured clinical presentations 
without any laboratory results for each patient. Therefore, we might not be able to perform 
the severity- adjusted (such as using the MELD scores) in-hospital mortality.
This study has a few potential limitations. Our analysis may be limited by the accuracy of 
the NIS database, which is based primarily on medical record coding. We acknowledge the 
deficiencies of using ICD-9 codes to identify secondary diagnosis of AH during the 
hospitalization. In certain circumstances, the ICD-9 for jaundice and hepatic encephalopathy 
were used as the primary admission diagnosis, and in fact such presentation might be 
secondary to underlying AH. One would argue that the overall mortality rate for subjects 
with AH in our study was much lower than previously reported 1, 2. We would like to 
emphasize that the mortality rate based on the NIS data was only confined to those cases 
who died while hospitalization. In general, the short term (30-day mortality) for severe 
alcoholic hepatitis is ~30%–50% 1, 15. Unfortunately, the NIS dataset did not provide any 
information regarding patient’s outcomes once he/she was released from the hospital. 
Despite these shortcomings, our study is strengthened by the use of a database that 
represents a wide variety of U.S. medical centers and patient populations.
In summary, we found the increase in AH-related hospitalization during the study period, 
despite the decreasing in the in-hospital mortality rate. Our results documented significant 
healthcare cost and utilization among hospitalized AH patients. Our findings should alert 
healthcare provider for better screening, education, and interventions among abusive 
drinkers aimed at promoting alcohol abstinence, thus preventing episodes of AH 15.
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Figure 1. 
(A) Rate of hospitalization for the diagnosis of AH in the United States from 2002–2010, 
(B) Inpatient mortality for the diagnosis of AH from 2002–2010, (C) Rate of sepsis, renal 
failure and GI bleed among patients who died during hospitalization from 2002–2010, and 
(D) Additional total hospital charges for the diagnosis of AH from 2002–2010, using the 
charges in 2002 as the reference.
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